Red Yeast Rice Extract reduces cholesterol and inflammation and improves heart function
Cardiac Syndrome X (not to be confused with Metabolic Syndrome X) is a clinical condition that produces angina-like chest pain during exertion with signs of poor blood flow to the heart (ischemia). The difference between this and coronary artery disease is that there is no clogging of the hearts arteries. This syndrome is found more often in pre-menopausal women and it is connected to conditions such as panic attacks and fibromyalgia.
In this study 36 patients with Cardiac Syndrome X were randomly given either a Chinese Red Yeast Rice Extract or placebo for 90 days. The Red Yeast Rice Extract produced a significant 19% decrease in total cholesterol, 26% drop in LDL-cholesterol, and a 16% decrease in triglycerides compared with the start of the study.
The Red Yeast Rice Extract reduced adjusted CRP by 44% (log CRP). CRP is a risk factor for developing high blood pressure, cardiovascular disease, diabetes, and possibly colon cancer. Elevated CRP is a predictor of stroke, heart attack, and increased risk of dying. The Red Yeast Rice improved the ability to exercise by inhibiting stress on the heart muscle. The study was performed at Peking Union Medical College and is published in the December 27th, 2006 issue of the International Journal of Cardiology.
Green Tea?s EGCG may be useful for fighting colon cancer metastasis
20 antioxidant compounds thought to have cancer preventing effects were tested on colon cancer cells. The substances were tested to grade the ability to block invasion by the colon cancer cells into surrounding-healthy tissues, the growth of the cancer, and the ability to metastasize to the lungs. EGCG from Green Tea inhibited colon cancer metastasis to the lungs by 77%, and the soy isoflavone Genistein inhibited it by 44%. If the dosage of EGCG was increased it inhibited metastasis to the lung by a whopping 98%. EGCG significantly inhibited tumor growth and invasion. Antioxidant activity was not related to the ability to fight cancer.
The study was performed at Toyama Prefectural Institute for Pharmaceutical Research and is published in the January 2007 issue of Biological and Pharmaceutical Bulletin.